903522-29-2 Usage
Description
3,5-Difluoropyridine-4-carboxylic acid is an organic compound characterized by the presence of two fluorine atoms at the 3rd and 5th positions of the pyridine ring, with a carboxylic acid group attached at the 4th position. This unique structure endows it with specific chemical properties and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
3,5-Difluoropyridine-4-carboxylic acid is used as a key intermediate in the synthesis of pyridyl-fused lactam derivatives, which are important for the development of novel pharmaceutical compounds with potential therapeutic applications.
Used in Chemical Synthesis:
3,5-Difluoropyridine-4-carboxylic acid serves as a versatile building block in organic chemistry, particularly for the preparation of di-substituted isonicotinic acid (I821760). 3,5-Difluoropyridine-4-carboxylic acid can be further utilized in the synthesis of various pyridyl-fused lactam derivatives, expanding the scope of chemical compounds available for research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 903522-29-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,3,5,2 and 2 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 903522-29:
(8*9)+(7*0)+(6*3)+(5*5)+(4*2)+(3*2)+(2*2)+(1*9)=142
142 % 10 = 2
So 903522-29-2 is a valid CAS Registry Number.
InChI:InChI=1/C6H3F2NO2/c7-3-1-9-2-4(8)5(3)6(10)11/h1-2H,(H,10,11)
903522-29-2Relevant articles and documents
The discovery of potent small molecule cyclic urea activators of STING
Banerjee, Monali,Basu, Sourav,Ghosh, Rajib,Middya, Sandip,Pryde, David C.,Shrivastava, Ritesh,Surya, Arjun,Yadav, Dharmendra B.
supporting information, (2022/02/07)
STING mediates innate immune responses that are triggered by the presence of cytosolic DNA. Activation of STING to boost antigen recognition is a therapeutic modality that is currently being tested in cancer patients using nucleic-acid based macrocyclic STING ligands. We describe here the discovery of 3,4-dihydroquinazolin-2(1H)-one based 6,6-bicyclic heterocyclic agonists of human STING that activate all known human variants of STING with high potency.
